IMPACT OF ANTI-TUBERCULOSIS DRUGS ON THE EXPRESSION OF CYTOCHROME-ASSOCIATED GENES

Main Article Content

LAWAL DANJUMA
SURESH KUMAR SUBBIAH

Abstract

The impact of Tuberculosis (TB) drugs on liver and kidney bio-indicators as well as histological architecture has been investigated since the inception of the drugs, with little or no sufficient data on the impact of the drugs at gene or molecular level. High through put analysis such as Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR), Microarray, Proteomics, Nano-strings and Next generation Sequencing (NGS) are normally employed to ascertain the level of damage cause by the drugs at molecular level. As such the expression levels of the genes can be determined, whether they are up regulated or down regulated, and compared the fold change with samples of the control group. The up regulation or down regulation of gene due to chemotherapy is an indicator of anomaly in a particular gene, and that can lead to the malfunction of the affected gene. The up regulation of gland secretion gene can lead to over secretion of hormone and also down regulation can lead to under secretion, and the overall biological process taking place in body can be halt and some biological functions can be obstructed. This review is aimed at investigating the impact of anti-tuberculosis drugs on the expression of cytochrome-associated genes, and to elaborate how some of the physiological processes of the body are affected by the up regulated or down regulated genes.

Keywords:
Anti-tuberculosis drugs, gene-expression, dysregulated-genes, cytochrome-associated genes, kidney, liver

Article Details

How to Cite
DANJUMA, L., & SUBBIAH, S. K. (2022). IMPACT OF ANTI-TUBERCULOSIS DRUGS ON THE EXPRESSION OF CYTOCHROME-ASSOCIATED GENES. Journal of Disease and Global Health, 15(3), 1-8. https://doi.org/10.56557/jodagh/2022/v15i37981
Section
Case Report

References

Lawal Danjuma, Mok Pooi Ling, Akon Higuchi, Rukman Awang Hamat, Palanisamy Arulselvan, Mariappan Rajan, Suresh Kumar Subbiah. Modulatory and Regenerative Potential of Transplanted Bone Marrow-Derived Mesenchymal Stem Cells on Rifampicin-Induced Kidney Toxicity. Journal of Regenerative Therapy. 2018;9(1):100- 110.

Santhosh S, Sini TK, Anandan R, Mathew PT. Effect of chitosan supplementation on antitubercular drugs-induced hepatotoxicity in rats. Toxicology. 2006;219: 53-59.

Kikkawa R, Fujikawa M, Yamamoto T, Hamada Y, Yamada, H. and Horii I. In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system. J. Toxicol. Sci. 2006;31: 23-34.

Viswanatha Swamy AHM, Rucha V, Kulkarni Koti BC, Gadad PC, Thippeswamy AHM, Aparna Gore. Hepatoprotective Effect of Cissus quadrangularis Stem Extract Against Rifampicin-induced Hepatotoxicity in Rats. Indian J Pharm Sci. 2012;74(2):183–187.

Awodele O, Akintonwa A, Osunkalu VO, Coker HAB. Modulatory activity of antioxidants against the toxicity of rifampicin in vivo. Rev. Inst. Med. Trop. São Paulo. 2010;52(1):43-46.

Rekha VV, Santha T, Jawahar MS. Rifampicin induced renal toxicity during retreatment of patients with pulmonary tuberculosis. J Assoc Physician India. 2005;53:811-3.

Santhosh S, Sini TK, Anandan R, Mathew PT. Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur. J. Pharmacol. 2007; 572:69-73.

Balamurugan K, Vanithakumari G, Indra N. Effect of rifampicin on certain biochemical parameter in the liver of albino rats. Internet J. Toxicol. 2009;6(1).

Rafiq S, Iqbal T, Jamil A, Khan FH. Pharmacokinetic studies of rifampicin in healthy volunteers and tuberculosis patients. Int. J. Agric. Biol. 2010;12(3):391-395.

Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of Silymarin. Heptol, Res. 2005;31:132-135.

Eminzade S, Uras F, Izzettin FV. Silymarin Protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr. Metab. 2008;5:18.

Pal R, Rana SV, Vaiphei K, Singh K. Isoniazid-rifampicin induced lipid changes in rats. Clin. Chem. Acta. 2008;389:55-60.

Marzouk M, Hassaneen S, Hussein H, Sammaan HA. Ameliorative effect of Mepacure against rimactazid-induced hepatotoxicity in rats. Aust. J. Basic Appl. Sci. 2009;3(3):2350-2354.

Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: Current and future therapies. J. Hepatol. 2010;52:258– 271.

Peters J, Block W, Oswald S, Freyer J, Grube M, Kroemer HK, et al. Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. Drug Metab. Dispos. 2011;39:1643–1649.

Vilas-Boas V, Silva R, Palmeira A, Sousa E, Ferreira LM, Branco PS, et al. Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate. Plos One. 2013;8: e74425.

Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int. J. Antimicrob. Agents. 2013;41:484–487.

Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet. 2003;42:819-850.

Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampicin, rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 2013;29:1–12.

Mottino AD. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 200;14:7068.

Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, Bruhn O, et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol. Pharmacol. 2011;80:314–320.

Benson EA, Eadon MT, Desta Z, Liu Y, Lin H, Burgess KS, et al. Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Frontier in Pharmacology, 2016; 7(111):1-13.

Liao Y, Zhang LS, Peng SQ. Gene Expression Profiles of Rifampicin-Injured Rat Liver Using cDNA Microarray. Chinese Journal of New Drugs. 2011;20(13):1212-1216.

Liao Y, Zhang LS, Peng SQ. Proteomic Analysis Isoniazid Toxicity in Rat Liver. Chinese Journal of New Drugs. 2011;20(1):18-23.

Liao Y, Zhang LS, Peng SQ. Gene Expression Profiles in Injured Rat Liver Induced by Isoniazid and Rifampicin Using cDNA Microarray. Chinese Journal of New Drugs. 2015;24(11):1278-1284.

Ju-Hyun K, Woong SN, Sun JK, Oh KK, Eun JS, Jung JJ, et al. Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoprteomics in Mice. International Journal of Molecular Sciences. 2017;18(1417):1-13.

Brewer CT, Chen T. PXR variants: The impact on drug metabolism and therapeutic responses. Acta Pharm. Sin. B. 2016;6:441–449.

Yan J, Xie W. A brief history of the discovery of PXR and CAR as xenobiotic receptors. Acta Pharm. Sin. B. 2016;6:450–452.

Huang JH, Zhang C, Zhang DG, Li L, Chen X, Xu DX. Rifampicin-induced hepatic lipid accumulation: Association with up-regulation of peroxisome proliferator-activated receptor gamma in mouse liver. Plos One. 2016; 11:e0165787.

Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie E, Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J. Biol. Chem. 1991;266:11341–11346.

Londos C, Brasaemle DL, Schultz CJ, Segrest JP, Kimmel AR, Perilipins ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin. Cell Dev. Biol. 1999;10:51–58.

Brasaemle DL, Subramanian V, Garcia A, Marcinkiewicz A, Rothenberg A. Perilipin a and the control of triacylglycerol metabolism. Mol. Cell. Biochem. 2009;326: 15–21.

Dalen KT, Schoonjans K, Ulven SM, Weedon-Fekjaer MS, Bentzen TG, Koutnikova H, et al. Adipose tissue expression of the lipid droplet–associating proteins S3–12 and perilipin is controlled by peroxisome proliferator—Activated receptor-γ. Diabetes. 2004;53:1243–1252.

Straub BK, Stoeffel P, Heid H, Zimbelmann R, Schirmacher P. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology. 2008;47:1936–1946.

Fujii H, Ikura Y, Arimoto J, Sugioka K, Iezzoni JC, Park SH, et al. Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J. Atheroscler. Thromb. 2010;16: 893–901.

Enriquez-Cortina C, Almonte-Becerril M, Clavijo-Cornejo D, Palestino-Domínguez M, Bello-Monroy O, Nuño N, et al. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage. Toxicol. Sci. 2013;135:26–36.

Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen, R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J. Gastroenterol. Hepatol. 2008;23:192–202.

Zhang WV, Ramzan I, Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J. Pharmacol. Exp. Ther. 2007;322: 770–777.

Donato M, Jimenez N, Serralta A, Mir J, Castell J, Gómez-Lechón M. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol. In-vitro. 2007;21:271–276.

Hewitt NJ, Gómez Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 2007;39:159–234.

Bishop-Bailey D, Thomson S, Askari A, Faulkner A, Wheeler-Jones C. Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism. Annu. Rev. Nutr. 2014;34:261–279.

Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, et al. Het0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br. J. Pharmacol. 2001;133:325–329.

Sacerdoti D, Balazy M, Angeli P, Gatta A, McGiff JC. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J. Clin. Investig. 1997;100:1264.

Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, Tirona R.G. Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point oral midazolam microdose phenotype in healthy subjects. Basic Clin. Pharmacol. Toxicol. 2016;118:284–291.

Marde Arrhen Y, Nylen H, Lovgren- Sandblom A, Kanebratt KP, Wide K, Diczfalusy UA. Comparison of 4β-hydroxycholesterol: Cholesterol and 6β-hydroxycortisol: Cortisol as markers of CYP3A4 induction. Br. J. Clin. Pharmacol. 2013;75:1536–1540.

Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br. J. Clin. Pharmacol. 2011;71:183–189.

Galal AM, Walker LA, Khan IA. Induction of gst and related events by dietary phytochemicals: Sources, chemistry, and possible contribution to chemoprevention. Curr. Top. Med. Chem. 2015;14: 2802–2821.

Danjuma L. Therapeutic potentials of bone marrow derived mesenchymal stem cell in averting organ damage due to rifampicin induced toxicity in animal models. PhD Thesis submitted to University Putra Malaysia. 2018;173-179.

Lawal D, Mok PL, Akon H, Rukman AH, Palanisamy A, Mariappan R, Suresh KS. Gene Expression Changes in Liver of Wistar Rats and their Progeny Due Rifampicin Treatment of Tuberculosis and the Regenerative potentials of Bone-Marrow Derived Mesenchymal Stem Cells. Accepted for publication in Scientific Report Journal; 2018.

Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE. et al. Emerging transporters of clinical importance: An update from the International Transporter Consortium. Clin. Pharmacol. Ther. 2013;94: 52–63.

Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010;9:215–236.

Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J. Med. Chem. 2011; 54:4548–4558.

Wieser M, Stadler G. Jennings P, Streubel B, Pfaller W, Ambros P, et al. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am. J. Physiol. Renal Physiol. 2008;295:1365–1375.

Herbert BS, Grimes BR, Xu WM, Werner M, Ward C, Rossetti S, et al. A telomerase immortalized human proximal tubule cell line with a truncation mutation (Q4004X) in polycystin-1. PLoS ONE. 2013;8:e55191.

DOI: 10.1371/journal.pone.0055191

Shu Y, Bello CL, Mangravite LM, Feng B, Giacomini KM. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J. Pharmacol. Exp. Ther. 2001;299:392– 398.

Cheng X, Klaassen CD. Regulation of mRNA expression of xenobiotic transporters by the pregnane x receptor in mouse liver, kidney, and intestine. Drug Metab. Dispos. 2006;34:1863–1867.